TARA-002 (NCT05951179)

Name: TARA-002 trial for Non-muscle Invasive Bladder Cancer (NCT05951179)
Uploaded: 2026-10-31T21:44:05.125Z
Duration: 1 min 31 s
Description: TARA-002 trial for Non-muscle Invasive Bladder Cancer (NCT05951179). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05951179.

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer: a one-minute explainerNCT059511791 min

TARA-002 trial for Non-muscle Invasive Bladder Cancer (NCT05951179). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with active high-grade bladder carcinoma in situ without muscle invasion, with or without Ta/T1 tumors. Eligible groups are BCG-naive, remotely BCG-exposed, or BCG-unresponsive.

The idea: TARA-002 contains inactivated bacteria intended to stimulate an immune attack. It is placed inside the bladder weekly for six weeks. Response determines another induction course or maintenance; eligible patients continue scheduled maintenance through month 24. Researchers measure complete responses and safety. Penicillin allergy excludes participation.

This phase 2 study plans 131 patients. Protara Therapeutics sponsors it; 36 US sites are recruiting.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.